The platform uniquely integrates four features: (1) MRI-guided tumor localization via T2-weighted contrast, (2) Targeted recognition of PSMA-positive prostate cancer cells by Glu-urea-Lys. The gene discussed is FOLH1; the disease is prostate cancer.